# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K142609   
B. Purpose for Submission: New Device   
C. Measurand: Nortriptyline and Buprenorphine   
D. Type of Test: Qualitative chromatographic immunoassay   
E. Applicant: Guangzhou Wondfo Biotech Co., Ltd.   
F. Proprietary and Established Names: CR3 Keyless Split Sample Cup Nortriptylin   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DJG</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR part 862.3650Opiate test system</td><td rowspan=1 colspan=1>Toxicology (91)</td></tr><tr><td rowspan=1 colspan=1>LFG</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR part 862.3910Tricyclic antidepressant drugstest system</td><td rowspan=1 colspan=1>Toxicology (91)</td></tr></table>

# H. Intended Use:

1. Intended use(s): Please see Indications for Use below.

2. Indication(s) for use:

CR3 Keyless Split Sample Cup Nortriptyline–Buprenorphine is a rapid test for the qualitative detection of Nortriptyline (a major metabolite of Tricyclic Antidepressants) and Buprenorphine in human urine at a cutoff concentration of $1 0 0 0 \mathrm { n g / m L }$ and $1 0 \mathrm { n g / m L }$ , respectively. The test is the first step in a two-step process. The second step is to send the sample for laboratory testing if preliminary positive results are obtained. The test is intended for over-the-counter and for prescription use.

The test may yield preliminary positive results even when prescription drugs including Tricyclic Antidepressants and Buprenorphine are ingested, at prescribed doses; it is not intended to distinguish between prescription use or abuse of these drugs. There are no uniformly recognized cutoff concentration levels for Nortriptyline and Buprenorphine in urine. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

For in vitro diagnostic use only.

3. Special conditions for use statement(s): For Prescription and Over-the-counter Use

4. Special instrument requirements: Not applicable; this is a visually read single use device.

# I. Device Description:

The CR3 Keyless Split Sample Cup Nortriptyline–Buprenorphine test uses immunochromatographic assays for nortriptyline and buprenorphine. The test is a lateral flow system for the qualitative detection of nortriptyline and buprenorphine in human urine.

# J. Substantial Equivalence Information:

1. Predicate device name(s): UCP Multi-Drug Test Key Cups

2. Predicate 510(k) number(s):

k132812

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indication(s)for use</td><td rowspan=1 colspan=1>For the qualitative determination ofdrugs of abuse in human urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assaysbased on the principle of antigenantibody immunochemistry.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>SpecimenType</td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut Off Values</td><td rowspan=1 colspan=1>Nortriptyline: 1000ng/mlBuprenorphine: 10ng/ml</td><td rowspan=1 colspan=1>Same for TricyclicAntidepressant(Nortriptyline) andBuprenorphine</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Cup</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conditions forUse</td><td rowspan=1 colspan=1>Over-the-Counter &amp; PrescriptionUse</td><td rowspan=1 colspan=1>Over-the-counter</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None were referenced.

# L. Test Principle:

The CR3 Keyless Split Sample Cup Nortriptyline - Buprenorphine test is a rapid flow chromatographic immunoassay for the qualitative detection of Nortriptyline and Buprenorphine in urine samples. Each assay uses a mouse monoclonal anti-drug antibodydye conjugate, fixed drug-protein conjugates, and anti-mouse IgG polyclonal antibodies coated on the test membranes. When the absorbent end of the test is immersed into a urine sample, the urine is absorbed into the device by capillary action and mixes with the antibodydye conjugate, flowing across the pre-coated membrane. At analyte concentrations below the target cut-off, antibody-dye conjugates bind to the drug-protein conjugate immobilized in the

Test Region (T) of the device. This produces a colored test line that indicates a negative result. When analyte concentration is above the cut-off, analyte molecules bind to the antibody-dye conjugate, preventing the antibody-dye conjugate from binding to the drugprotein conjugate immobilized in the Test Region (T) of the device. No colored band shows in the Test Region, indicating a potentially positive result. A band should form in the Control Region (C) of the device regardless of the presence of drug or metabolite in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision studies were carried out for samples with concentrations of - $\cdot 1 0 0 \%$ cut-off, $- 7 5 \%$ cut-off, $- 5 0 \%$ cut-off, $- 2 5 \%$ cut-off, at the cut-off, $+ 2 5 \%$ cut-off, $+ 5 0 \%$ cut-off, $+ 7 5 \%$ cut-off and $+ 1 0 0 \%$ cut-off. For each concentration, tests were performed two runs per day for 25 days. All sample aliquots were masked and randomized. The results obtained are summarized in the following tables:

# For Nortriptyline testing

<table><tr><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>-100%cut-off</td><td rowspan=1 colspan=1>-75%cut-off</td><td rowspan=1 colspan=1>-50%cut-off</td><td rowspan=1 colspan=1>-25%cut-off</td><td rowspan=1 colspan=1>cut-off</td><td rowspan=1 colspan=1>+25%cut-off</td><td rowspan=1 colspan=1>+50%cut-off</td><td rowspan=1 colspan=1>+75%cut-off</td><td rowspan=1 colspan=1>+100%cut-off</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>44+/6-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

# For Buprenorphine testing

<table><tr><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>-100%cut-off</td><td rowspan=1 colspan=1>-75%cut-off</td><td rowspan=1 colspan=1>50%cut- off</td><td rowspan=1 colspan=1>-25%cut-off</td><td rowspan=1 colspan=1>cut-off</td><td rowspan=1 colspan=1>+25%cut-off</td><td rowspan=1 colspan=1>+50%cut-off</td><td rowspan=1 colspan=1>+75%cut-off</td><td rowspan=1 colspan=1>+100%cut-off</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>42+/8-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

b. Linearity/assay reportable range:

Not applicable.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Shelf stability for the CR3 Keyless Split Sample Cup Nortriptyline - Buprenorphine was performed using accelerated and real-time stability testing. Protocols and acceptance criteria were reviewed and found to be acceptable. The sponsor claims that the device is stable at $4 { - } 3 0 \mathrm { { ^ \circ C } }$ for 18 months.

Control materials are not provided with the device. The labeling provides information on how to obtain control materials.

d. Detection limit:

Not applicable.

e. Analytical specificity:

Potential interfering substances found in human urine of physiological or pathological conditions were added at a concentration of $1 0 0 \mu \mathrm { g / m L }$ to drug-free urine and to urine containing target drugs (nortriptyline or buprenorphine) at $2 5 \%$ below and $2 5 \%$ above the cut-off. The samples were tested using three lots of the CR3 Keyless Split Sample Cup Nortriptyline - Buprenorphine by three different operators. The compounds below showed no interference:

# Nortriptyline

Erythromycin   
$\beta$ -Estradiol   
Estrone-3-sulfate   
Ethyl-p-aminobenzoate   
Fenoprofen   
Furosemide   
Gentisic acid   
Hemoglobin   
Hydralazine   
Hydrochlorothiazide   
Oxycodone   
Oxymetazoline   
Papaverine   
Penicillin-G   
Pentazocine hydrochloride   
Pentobarbital   
Perphenazine   
Phencyclidine   
Phenelzine   
Phenobarbital   
4-Acetamidophenol   
Acetophenetidin   
N-Acetylprocainamide   
Acetylsalicylic acid   
Aminopyrine   
Amobarbital   
Amoxicillin   
Ampicillin   
L-ascorbic acid   
DL-Amphetamine   
sulfate   
Apomorphine   
Aspartame   
Atropine

Hydrocodone Hydrocortisone O-Hydroxyhippuric acid

Phentermine   
$\beta$ -Phenylethylamine   
Trans-2-   
phenylcyclopropylamine   
hydrochloride   
L-Phenylephrine   
Phenylpropanolamine

Benzilic acid p-Hydroxyamphetamine Benzoic acid $\mathfrak { p }$ -Hydroxymethamphetamine

Benzoylecgonine   
Benzphetamine   
Bilirubin   
$( \pm )$ - Brompheniramine   
Caffeine   
Cannabidiol   
Cannabinol   
Chloralhydrate   
Chloramphenicol   
Chlorothiazide   
$( \pm )$ Chlorpheniramine   
Chlorpromazine   
Chlorquine   
Cholesterol   
Clonidine   
Cocaethylene   
Prednisolone   
Prednisone   
Procaine   
DL-Propanolol   
D-Propoxyphene   
D-Pseudoephedrine   
Quinacrine   
Quinidine   
Quinine   
Ranitidine   
Salicylic acid   
Secobarbital   
Serotonin   
Sulfamethazine   
Sulindac   
Tetracycline   
3-Hydroxytyramine   
Ibuprofen   
Iproniazid   
$( \pm ) -$ Isoproterenol   
Isoxsuprine   
Ketamine   
Ketoprofen   
Labetalol   
Loperamide   
MDE   
Meperidine   
Meprobamate   
Methadone   
(L)Methamphetamine   
Methoxyphenamine   
$( \pm ) - 3 , 4 -$   
Methylenedioxyamphetami   
ne hydrochloride   
$^ { ( + ) 3 , 4 }$ -   
Methylenedioxymethamphe   
tamine hydrochloride   
Morphine-3- $\cdot \beta$ -Dglucuronide

Cocaine hydrochloride

Tetrahydrocortisone, 3-acetate

Codeine

Cortisone   
(-) Cotinine   
Creatinine   
Deoxycorticosterone   
Dextromethorphan   
Diclofenac   
Diflunisal   
Digoxin   
Diphenhydramine   
Doxylamine   
hetamine hydrochloride   
Codeine   
Tetrahydrocortisone 3-( $\beta$ -D  
glucuronide)   
Tetrahydrozoline   
Thiamine   
Thioridazine   
DL-Tyrosine   
Tolbutamide   
Triamterene   
Trifluoperazine   
Trimethoprim   
Tryptamine   
DL-Tryptophan   
Tetrahydrocortisone 3-   
( $\beta$ -D-glucuronide)   
Tetrahydrozoline   
Thiamine   
Thioridazine   
DL-Tyrosine   
Tolbutamide   
Triamterene   
Trifluoperazine   
Trimethoprim   
Tryptamine   
DL-Tryptophan   
Morphine sulfate   
Nalidixic acid   
Naloxone   
Naltrexone   
Naproxen   
Niacinamide   
Nifedipine   
Norcodeine   
Norethindrone   
D-Norpropoxyphene 3-acetate Morphine-3- $\cdot \beta$ - Dglucuronide Morphine sulfate Nalidixic acid Naloxone Naltrexone Naproxen Niacinamide Nifedipine Norcodeine Norethindrone D-Norpropoxyphene   
Cortisone   
(-) Cotinine   
Creatinine   
Deoxycorticosterone   
Dextromethorphan   
Diclofenac   
Diflunisal   
Digoxin   
Diphenhydramine   
Doxylamine

Ecgonine hydrochloride Ecgonine methylester Ephedrine (L) - Epinephrine

Noscapine Oxalic acid Oxazepam Oxolinic acid

Tyramine Uric acid Verapamil Zomepirac

# Buprenorphine

4-Acetamidophenol   
Acetophenetidin   
N-Acetylprocainamide   
Acetylsalicylic acid   
Aminopyrine   
Amobarbital   
Amoxicillin   
Ampicillin   
L-ascorbic acid   
DL-Amphetamine sulfate   
Apomorphine   
Aspartame   
Atropine   
Erythromycin   
$\beta$ -Estradiol   
Estrone-3-sulfate   
Ethyl-p-aminobenzoate   
Fenoprofen   
Furosemide   
Gentisic acid   
Hemoglobin   
Hydralazine   
Hydrochlorothiazide   
Hydrocodone   
Hydrocortisone   
O-Hydroxyhippuric acid   
Oxycodone   
Oxymetazoline   
Papaverine   
Penicillin-G   
Pentazocine hydrochloride   
Pentobarbital   
Perphenazine   
Phencyclidine   
Phenelzine   
Phenobarbital   
Phentermine   
$\beta$ -Phenylethylamine   
Trans-2-   
phenylcyclopropylamine   
hydrochloride   
L-Phenylephrine   
Phenylpropanolamine

Benzilic acid Benzoic acid

Benzoylecgonine   
Benzphetamine   
Bilirubin   
$( \pm )$ - Brompheniramine   
Caffeine   
Cannabidiol   
Cannabinol   
Chloralhydrate   
Chloramphenicol   
Chlorothiazide   
$( \pm )$ Chlorpheniramine   
Chlorpromazine   
Chlorquine   
Cholesterol   
Clonidine   
Cocaethylene   
Prednisolone   
Prednisone   
Procaine   
DL-Propanolol   
D-Propoxyphene   
D-Pseudoephedrine   
Quinacrine   
Quinidine   
Quinine   
Ranitidine   
Salicylic acid   
Secobarbital   
Serotonin   
Sulfamethazine   
Sulindac   
Tetracycline   
p-Hydroxyamphetamine   
p-Hydroxy  
methamphetamine   
3-Hydroxytyramine   
Ibuprofen   
Iproniazid   
$( \pm )$ - Isoproterenol   
Isoxsuprine   
Ketamine   
Ketoprofen   
Labetalol   
Loperamide   
MDE   
Meperidine   
Meprobamate   
Methadone   
(L)Methamphetamine   
Methoxyphenamine   
$( \pm ) - 3 , 4 -$   
Methylenedioxyamphetamin   
e hydrochloride   
$( + ) 3 , 4 -$   
Methylenedioxymethamp

Cocaine hydrochloride

Tetrahydrocortisone,

# hetamine hydrochloride Codeine

Cortisone   
(-) Cotinine   
Creatinine   
Deoxycorticosterone   
Dextromethorphan   
Diclofenac   
Diflunisal   
Digoxin   
Diphenhydramine   
Doxylamine   
Ecgonine hydrochloride   
Ecgonine methylester   
Ephedrine   
(L) - Epinephrine

3-acetate Morphine-3- $\cdot \beta \cdot$ - Dglucuronide Morphine sulfate Nalidixic acid Naloxone Naltrexone Naproxen Niacinamide Nifedipine Norcodeine Norethindrone D-Norpropoxyphene Noscapine Oxalic acid Oxazepam Oxolinic acid

#

Tetrahydrocortisone 3- $\beta$ -   
D-glucuronide)   
Tetrahydrozoline   
Thiamine   
Thioridazine   
DL-Tyrosine   
Tolbutamide   
Triamterene   
Trifluoperazine   
Trimethoprim   
Tryptamine   
DL-Tryptophan   
Tyramine   
Uric acid   
Verapamil   
Zomepirac

Cross-reactivity was tested by adding various drug metabolites and other components that are likely to be present in negative urine samples. The drug metabolites and other components were tested at different concentrations. These samples were tested using three lots of the CR3 Keyless Split Sample Cup Nortriptyline–Buprenorphine by three different operators. The obtained lowest detectable concentration was used to calculate the cross-reactivity. Results are shown below:

# Nortriptyline

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>%Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Nortriptyline</td><td rowspan=1 colspan=1>Positive at 1000 ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Nordoxepine</td><td rowspan=1 colspan=1>Positive at 1,000 ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Trimipramiine</td><td rowspan=1 colspan=1>Positive at 3,000 ng/mL</td><td rowspan=1 colspan=1>33%</td></tr><tr><td rowspan=1 colspan=1>Amitriptyline</td><td rowspan=1 colspan=1>Positive at 1,500 ng/mL</td><td rowspan=1 colspan=1>67%</td></tr><tr><td rowspan=1 colspan=1>Promazine</td><td rowspan=1 colspan=1>Positive at 1,500 ng/mL</td><td rowspan=1 colspan=1>67%</td></tr><tr><td rowspan=1 colspan=1>Desipramine</td><td rowspan=1 colspan=1>Positive at 200 ng/mL</td><td rowspan=1 colspan=1>500%</td></tr><tr><td rowspan=1 colspan=1>Imipramine</td><td rowspan=1 colspan=1>Positive at 400 ng/mL</td><td rowspan=1 colspan=1>250%</td></tr><tr><td rowspan=1 colspan=1>Clomipramine</td><td rowspan=1 colspan=1>Positive at 12,500 ng/mL</td><td rowspan=1 colspan=1>8%</td></tr><tr><td rowspan=1 colspan=1>Doxepine</td><td rowspan=1 colspan=1>Positive at 2,000 ng/mL</td><td rowspan=1 colspan=1>50%</td></tr><tr><td rowspan=1 colspan=1>Maprotiline</td><td rowspan=1 colspan=1>Positive at 2,000 ng/mL</td><td rowspan=1 colspan=1>50%</td></tr><tr><td rowspan=1 colspan=1>Promethazine</td><td rowspan=1 colspan=1>Positive at 25,000 ng/mL</td><td rowspan=1 colspan=1>4%</td></tr></table>

# Buprenorphine

<table><tr><td rowspan=1 colspan=1>BUP(Buprenorphine,Cut-off=10 ng/mL)</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>Positive at 10ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine -3-D-Glucuronide</td><td rowspan=1 colspan=1>Positive at 15ng/mL</td><td rowspan=1 colspan=1>67%</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>Positive at 20ng/mL</td><td rowspan=1 colspan=1>50%</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine -3-D-Glucuronide</td><td rowspan=1 colspan=1>Positive at 200ng/mL</td><td rowspan=1 colspan=1>5%</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr></table>

Effect of Specific Gravity and pH

Twelve urine samples of normal, high, and low specific gravity ranges (1.000 to 1.035) were collected and spiked with either Nortriptyline or Buprenorphine at $2 5 \%$ below and $2 5 \%$ above the corresponding cut-off levels. The samples were tested using three lots of the CR3Keyless Split Sample Cup Nortriptyline–Buprenorphine by three different operators.

The pH of an aliquot negative urine pool was adjusted to pH ranges of 4.00 to 9.00 in $1 \mu \mathrm { H }$ unit increments and spiked with Nortriptyline or Buprenorphine at $2 5 \%$ below and $2 5 \%$ above the corresponding cut-off levels. The samples were tested using three lots of the CR3Keyless Split Sample Cup Nortriptyline–Buprenorphine by three different operators.

The device performance was found to not be affected by varying urine specific gravity and pH.

f. Assay cut-off:

Analytical performance of the device around the claimed cutoff is described in precision section (M.1.a.) above.

2. Comparison studies:

# a. Method comparison with predicate device:

The method comparison for the CR3 Keyless Split Sample Cup Nortriptyline– Buprenorphine was performed by three operators. Eighty (40 negative and 40 positive) unaltered clinical samples were masked, randomized and tested. The obtained test results were compared to GC/MS results. The results are presented in the table below:

# Nortriptyline

<table><tr><td rowspan=1 colspan=1>Operators</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegative byGC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Betweenthe cutoffand +50%)</td><td rowspan=1 colspan=1>HighPositive byGC/MS(greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant table:

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample number</td><td colspan="1" rowspan="1">GC/MS result</td><td colspan="1" rowspan="1">Viewer result</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">TCAC1061</td><td colspan="1" rowspan="1">919</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">TCAC1062</td><td colspan="1" rowspan="1">964</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">TCAC1063</td><td colspan="1" rowspan="1">944</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">TCAC1064</td><td colspan="1" rowspan="1">1082</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">TCAC1065</td><td colspan="1" rowspan="1">1012</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">TCA 1218</td><td colspan="1" rowspan="1">1245</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">TCAC1034</td><td colspan="1" rowspan="1">754</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">TCAC1061</td><td colspan="1" rowspan="1">919</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">TCAC1062</td><td colspan="1" rowspan="1">964</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">TCAC1063</td><td colspan="1" rowspan="1">944</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">TCAC1064</td><td colspan="1" rowspan="1">1082</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">TCAC1065</td><td colspan="1" rowspan="1">1012</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">TCAC1093</td><td colspan="1" rowspan="1">1237</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">TCAC1061</td><td colspan="1" rowspan="1">919</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">TCAC1062</td><td colspan="1" rowspan="1">964</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">TCAC1063</td><td colspan="1" rowspan="1">944</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">TCAC1064</td><td colspan="1" rowspan="1">1082</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">TCAC1065</td><td colspan="1" rowspan="1">1012</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">TCAC1093</td><td colspan="1" rowspan="1">1237</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">TCA 1218</td><td colspan="1" rowspan="1">1245</td><td colspan="1" rowspan="1">negative</td></tr></table>

# Buprenorphine:

<table><tr><td rowspan=1 colspan=1>GroupOperators</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegativeby GC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>HighPositive byGC/MS(greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant table:

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample number</td><td colspan="1" rowspan="1">GC/MS result</td><td colspan="1" rowspan="1">viewer results</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BUPC1063</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BUPC1064</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BUP1217</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BUPC1061</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BUPC1062</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BUPC1093</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BUP1224</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUPC1063</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUPC1064</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUP1216</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUP1217</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUPC1061</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUPC1062</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUPC1091</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BUP1224</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUPC1033</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUPC1065</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUP1213</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUP1216</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUP1217</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUPC1061</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUPC1091</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BUP1224</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">negative</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.

b. Clinical specificity: Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Lay-user study

A lay user study was performed at three sites with 260 participants (20 tested drugfree samples, 120 tested nortriptyline samples, and 120 tested buprenorphine samples). They had diverse educational and professional backgrounds and ranged in age from 21 to $> 5 0$ years. Urine samples were prepared at the following concentrations; $- 1 0 0 \%$ , $+ / - 7 5 \%$ , $+ / - 5 0 \%$ , $+ / - 2 5 \%$ of the cut-off by spiking drug(s) into drug free-pooled urine specimens. The concentrations of the samples w ere confirmed by GC/MS. Each sample was aliquoted into individual containers, blind-labeled and randomized. Each participant was provided with the package insert, 1 blind labeled sample and a device. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1># ofSamples</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>%AgreementWith GC/MS</td></tr><tr><td rowspan=1 colspan=1>Drug -free</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=6 colspan=1>Nortriptyline</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=6 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr></table>

Lay-users were also given surveys on the ease of understanding the package insert instructions. All lay users indicated that the device instructions can be easily followed A Flesch-Kincaid reading analysis was performed on the package insert and the score revealed a reading grade level of less than 7.

# Temperature Strip

The temperature test strip that is a part of the test cup was evaluated for accuracy. The temperature test strip provides a reading in the temperature range of 32 to $3 8 \mathrm { { ^ \circ C } }$ . To test for accuracy, water samples were adjusted to different temperatures (32, 33, 34, 36, 37 and $3 8 ~ ^ { \circ } \mathrm { C }$ ) and added to device test cups. Technicians read the temperature on the strip on the cup and recorded the results. The temperature of the water samples were also measured with a separate thermometer. Results obtained from the temperature strip were consistent with the thermometer readings.

To validate the performance of the temperature test strip in the hands of the intended user, a user study was conducted. In this user study, 100 lay users filled the device test cups with urine according to the device labeling and used the temperature test strip to record the temperature of their samples. Results were compared to readings of the same samples by professionals. The study demonstrated that the lay users could accurately read the test strip. Urine samples in the study were within the temperature range of the test strip.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.